Education
About Us
Working with TipRanks
Follow Us
Oncolys BioPharma, Inc. (JP:4588)
:4588
4588 Stock Chart & Stats
¥953.00
-¥1.00(-0.20%)
At close: 4:00 PM EST
¥953.00
-¥1.00(-0.20%)
Day’s Range― - ―
52-Week Range¥458.00 - ¥3,415.00
Previous CloseN/A
Volume332.10K
Average Volume (3M)1.52M
Market Cap
¥65.56B
Enterprise Value¥49.64B
Total Cash (Recent Filing)¥1.39B
Total Debt (Recent Filing)¥366.79M
Price to Earnings (P/E)―
Beta1.90
Next Earnings
May 08, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-15.37
Shares Outstanding29,291,700
10 Day Avg. Volume2,742,450
30 Day Avg. Volume1,517,566
Financial Highlights & Ratios
PEG Ratio-4.72
Price to Book (P/B)8.90
Price to Sales (P/S)1247.26
P/FCF Ratio-18.32
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Manageable Leverage & Stronger Balance SheetLower leverage and a materially expanded balance sheet provide durable financial flexibility for a cash-burning R&D firm. Improved debt-to-equity and larger equity/assets give the company runway to fund trials, negotiate partnerships, and absorb losses without immediate refinancing pressure.
Positive Gross Profit Margin DynamicsSustained positive gross profit indicates the company’s core product economics can be favorable once scale or commercialization occurs. This structural strength means operating losses are driven more by SG&A/R&D choices than by unprofitable unit economics, allowing margin recovery via cost discipline or revenue scaling.
Focused R&D In Oncolytic Virus And Novel ModalitiesA focused biotech strategy targeting high‑unmet‑need oncology with novel modalities is a durable competitive position. High barriers to entry, IP protection and potential for high-value outcomes make the business model attractive long-term and increase partnership or licensing prospects that can fund development.
Bears Say
Collapsed And Declining Revenue TrendA multi-year collapse in revenue signals structural commercial weaknesses or one-off losses of income that reduce the firm's ability to scale. Persistently shrinking top line makes achieving operating leverage and funding ongoing R&D internally unlikely, increasing reliance on external capital and strategic deals.
Persistent Heavy Operating Cash OutflowsChronic negative operating cash flow and worsening free cash flow are durable funding risks for an R&D-stage biotech. Continuous cash burn forces recurring financings or dilution, constrains strategic optionality, and elevates execution risk if capital markets or partners become less available.
Large, Persistent Operating And Net LossesSustained large losses that persistently erode returns on equity threaten long-term solvency and shareholder value. Without a clear pathway to materially higher revenue or major cost reduction, ongoing deficits can deplete equity, limit reinvestment, and make long‑term commercialization plans tenuous.
Oncolys BioPharma, Inc. News
4588 FAQ
What was Oncolys BioPharma, Inc.’s price range in the past 12 months?
Oncolys BioPharma, Inc. lowest stock price was ¥458.00 and its highest was ¥3415.00 in the past 12 months.
What is Oncolys BioPharma, Inc.’s market cap?
Oncolys BioPharma, Inc.’s market cap is ¥65.56B.
When is Oncolys BioPharma, Inc.’s upcoming earnings report date?
Oncolys BioPharma, Inc.’s upcoming earnings report date is May 08, 2026 which is in 51 days.
How were Oncolys BioPharma, Inc.’s earnings last quarter?
Oncolys BioPharma, Inc. released its earnings results on Feb 06, 2026. The company reported -¥15.37 earnings per share for the quarter, missing the consensus estimate of N/A by -¥15.37.
Is Oncolys BioPharma, Inc. overvalued?
According to Wall Street analysts Oncolys BioPharma, Inc.’s price is currently Overvalued.
Does Oncolys BioPharma, Inc. pay dividends?
Oncolys BioPharma, Inc. does not currently pay dividends.
What is Oncolys BioPharma, Inc.’s EPS estimate?
Oncolys BioPharma, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Oncolys BioPharma, Inc. have?
Oncolys BioPharma, Inc. has 29,291,700 shares outstanding.
What happened to Oncolys BioPharma, Inc.’s price movement after its last earnings report?
Oncolys BioPharma, Inc. reported an EPS of -¥15.37 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 5.343%.
Which hedge fund is a major shareholder of Oncolys BioPharma, Inc.?
Currently, no hedge funds are holding shares in JP:4588
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Oncolys BioPharma, Inc.
Oncolys BioPharma Inc. engages in the research, development, manufacture, sale, import, and export of oncolytic viruses, drugs and medicines, and tumor diagnostic agents in Japan, the rest of Asia, and the United States. Its product pipeline includes Telomelysin (OBP-301), an oncolytic adenovirus that is in phase II clinical trial for the treatment of gastric cancer/gastroesophageal junction, head and neck, and esophageal cancers; and in phase I clinical trial for the treatment of hepatocellular carcinoma. The company's product pipeline also includes OBP-702, a telomerase-specific oncolytic adenovirus, which is in pre-clinical trial for the treatment of solid tumors; OBP-2011, which is in pre-clinical trial for the treatment of SARS-Cov-2 virus infection; OBP-601 (Censavudine), a nucleotide reverse transcriptase inhibitor that has completed the phase IIb clinical trial for the treatment of HIV infection; and OBP-801, a histone deacetylase inhibitor, which is in phase I clinical trial for the treatment of solid tumors, as well as in pre-clinical trial for ophthalmic use. In addition, it develops TelomeScan (OBP-401 and OBP-1101), a cancer detection drug, for detecting living circulating tumor cells in blood from cancer patients. Further, the company provides diagnostic drugs and inspection services. It has various licensing agreements with Okayama University, Osaka University, Kyoto Prefectural University of Medicine, Kagoshima University, Astellas Pharma Inc., Yale University, Biologics Consulting Group, Inc., Lonza Houston, Inc., Medigen Biotechnology Corp., and Liquid Biotech USA, Inc. Oncolys BioPharma Inc. was incorporated in 2004 and is headquartered in Tokyo, Japan.
Technical Analysis
Peptidream
―
OncoTherapy Science
―
CanBas Co., Ltd.
―
Chiome Bioscience Inc.
―
Takara Bio Inc.
―